Mahesan Subramaniam: Japan Brings Mitochondrial Therapy to the Frontline of Cardiology
Mahesan Subramaniam, Co-Founder of United Health Tourism, shared a post on LinkedIn:
“There is a moment in a cardiologist’s career when the tools run out — when the heart muscle has lost too many mitochondria, the tiny power plants that keep cardiac cells contracting rhythmically, and no drug can rebuild what ischemia has destroyed.
Researchers at Keio University School of Medicine in Tokyo have now intervened at precisely that biological level, injecting viable mitochondria harvested from a patient’s own healthy skeletal muscle directly into damaged cardiac tissue during bypass surgery.
The technique, validated in a Phase II clinical trial published in The Lancet (2025), enrolled 47 patients with severe ischemic heart failure unresponsive to maximal medical therapy. Within 72 hours of mitochondrial injection into the infarct border zone, cardiac output measurably improved in 89% of participants.
At six months, left ventricular ejection fraction — the gold standard metric of pumping efficiency — had increased from an average of 24% to 41%, crossing from dangerous territory into functional range.
Crucially, because the mitochondria were autologous (from the patient’s own body), immune rejection was a non-issue.
The biology underpinning this is both ancient and elegant. Mitochondria, which retain their own DNA from their bacterial ancestry, can be isolated, concentrated, and re-injected into energy-starved tissue where they are taken up by host cells through macropinocytosis and membrane fusion.
Once inside, they begin generating ATP within hours, rescuing cells that were in metabolic freefall. This bypasses the central limitation of stem-cell therapy: the weeks required for transplanted cells to differentiate and integrate.
The protocol is now being adapted for non-surgical delivery — an intracoronary catheter approach that could treat patients without open-chest access. If this succeeds, mitochondrial therapy could become a frontline cardiac rescue tool globally.
The deeper implication: we may have been thinking about heart repair at the wrong biological scale all along.
Source:
Keio University School of Medicine, The Lancet, 2025.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 17:01Kanishk Kumar: Discovering The Newest Advances in Hypercholesterolemia Research
-
Mar 26, 2026, 17:00Ifeanyichukwu Ifechidere: Breaking the INR Myth in Liver Disease
-
Mar 26, 2026, 16:57Georgiana Toma: Why Nutrition is a Hematologist’s Secret Weapon
-
Mar 26, 2026, 16:56Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
-
Mar 26, 2026, 16:39Faizan Khan: Cold Agglutinins and Their Effects on CBC Results
-
Mar 26, 2026, 16:38Strengthening Research and Partnerships at THSNA 2026 – NBDF
-
Mar 26, 2026, 16:38Gareth Owens: Advancing Patient Engagement in Cardiothoracic Surgery
-
Mar 26, 2026, 16:36Yan Leyfman: Episode 3 of The Translational Edge on Cancer Anticoagulation Is Now Live on Shuf
-
Mar 26, 2026, 15:50Vicky Kumar: How Best to Manage Patients with Patent Foramen Ovale After a Cryptogenic Stroke